Related Experiment Video

Updated: Mar 21, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R

Klaas de Lint1, Jos B Poell1, Hayssam Soueidan2

  • 1Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Cancer Systems Biology Center (CSBC), The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Molecular Cancer Therapeutics
|May 20, 2016
PubMed

Insights

Combining PI3K and IGF1R inhibitors shows promise for treating triple-negative breast cancer (TNBC). This dual therapy enhances sensitivity in TNBC cells, with IGF2BP3 expression potentially predicting treatment response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapy options.
  • PI3K pathway is crucial for TNBC proliferation, but PI3K inhibition alone has limited efficacy.
  • Identifying synergistic drug combinations is critical for effective TNBC treatment.

Purpose of the Study:

  • To identify kinases that synergize with PI3K inhibition in TNBC.
  • To evaluate the combination of PI3K and IGF1R inhibitors for TNBC treatment.
  • To identify potential biomarkers for predicting response to combination therapy.

Main Methods:

  • RNAi-based genetic screen to identify synergistic targets with PI3K inhibitor GDC-0941.
  • Pharmacologic inhibition of PI3K (GDC-0941) and IGF1R (OSI-906) in TNBC cell lines.
  • Assessing drug synergy and downstream pathway activity.
  • Analyzing IGF2BP3 expression as a predictive biomarker.

Main Results:

  • Knockdown of IGF1R significantly sensitized TNBC cells to PI3K inhibition.
  • The combination of PI3K and IGF1R inhibitors demonstrated synergistic effects in a subset of TNBC cell lines.
  • IGF1R inhibition further reduced PI3K pathway activity when PI3K was already inhibited.
  • IGF2BP3 expression levels correlated with sensitivity to the combination therapy.

Conclusions:

  • Combination therapy with PI3K and IGF1R inhibitors offers a potential therapeutic strategy for a subset of TNBC patients.
  • IGF1R is a viable target for combination therapy with PI3K inhibitors in TNBC.
  • IGF2BP3 expression may serve as a predictive biomarker for patient selection.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K